# Neumora Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Neumora Therapeutics, Inc.). ## Overview Neumora Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapies for brain and centrally mediated diseases. Its pipeline includes small-molecule drug candidates for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, obesity, and other neuroscience targets. ## Products & services • Navacaprant (NMRA-140), oral KOR antagonist for MDD • NMRA-511, V1aR antagonist for agitation in Alzheimer’s dementia • M4 PAM neuroscience franchise, including NMRA-861 and NMRA-898 • NMRA-215, oral NLRP3 inhibitor for obesity • Preclinical and clinical neuroscience drug development programs - **Clinical neuroscience candidates** (55%) — Late-stage and early clinical drug candidates for psychiatric and neurologic disorders. - **Preclinical neuroscience programs** (30%) — Discovery-stage programs targeting novel CNS mechanisms and disease pathways. - **Research platform and pipeline development** (15%) — Internal research efforts, target validation, and translational neuroscience work. - Navacaprant (NMRA-140), oral KOR antagonist for MDD - NMRA-511, V1aR antagonist for agitation in Alzheimer’s dementia - M4 PAM neuroscience franchise, including NMRA-861 and NMRA-898 - NMRA-215, oral NLRP3 inhibitor for obesity - Preclinical and clinical neuroscience drug development programs ## Customers Neumora does not currently sell commercial products; its near-term “customers” are clinical trial participants, investigators, and ultimately regulators and payers that determine whether its drug candidates can reach patients. If approved, its therapies would be used by physicians treating patients with major depressive disorder, Alzheimer’s-related agitation, obesity, and other CNS disorders. - **Clinical trial participants** (primary) — Patients and healthy volunteers enrolled in Phase 1, 1b, and Phase 3 studies to generate safety and efficacy data. - **Psychiatry and mental health providers** (primary) — Physicians and clinics that would prescribe navacaprant for major depressive disorder if approved. - **Neurology and dementia care providers** (secondary) — Specialists treating agitation associated with dementia due to Alzheimer’s disease, the target for NMRA-511. - **Future obesity treatment providers** (emerging) — Clinicians who may use NMRA-215 for obesity if clinical development and approval succeed. - Patients enrolled in clinical trials for neuroscience drug candidates - Physicians treating major depressive disorder and related CNS disorders - Specialists in Alzheimer’s disease agitation and dementia care - Future payers and health systems if products are approved - Regulators reviewing safety and efficacy data for approval ## Geography Neumora is headquartered in the United States and conducts its research and development from U.S.-based operations, including office space in Massachusetts. Its business is currently centered on U.S. clinical development and regulatory pathways, with future commercialization dependent on approvals in the U.S. and potentially other markets. - Headquartered in the United States - Clinical development and corporate operations are U.S.-based - Massachusetts office supports administrative and development work - Future market access depends on U.S. and foreign regulatory approvals - No product revenue geography disclosed because the company is pre-commercial ## Strategy Neumora’s strategy is to build a differentiated neuroscience pipeline around novel mechanisms of action for underserved brain diseases. The company is prioritizing late-stage development of navacaprant, advancing NMRA-511 and M4 PAM programs, and expanding into additional CNS and metabolic targets such as NMRA-215. - **Advance navacaprant through Phase 3** (short-term) — This is the most advanced program and the clearest path to potential first commercialization. - **Build clinical proof for NMRA-511** (short-term) — Positive signal-seeking data would support expansion into Alzheimer’s-related agitation. - **Advance M4 PAM franchise** (medium-term) — Multiple compounds diversify the pipeline and broaden the company’s neuroscience platform. - **Expand into obesity with NMRA-215** (medium-term) — Adds a new therapeutic area and another novel mechanism to the pipeline. - Advance navacaprant through pivotal Phase 3 development - Generate proof-of-concept data for NMRA-511 in Alzheimer’s agitation - Progress M4 PAM compounds into clinical testing - Expand the pipeline into obesity with NMRA-215 - Use novel CNS mechanisms to target underserved diseases ## Risks Neumora faces the typical risks of a clinical-stage biotech company: long development timelines, uncertain trial outcomes, and heavy dependence on regulatory approval. Because it has no commercial products, its future value depends on successful clinical data, intellectual property protection, and access to capital to fund ongoing development. - **Clinical development failure or delay** [critical] — Drug candidates may not show sufficient safety or efficacy, or trials may take longer than planned. - **Regulatory approval risk** [high] — FDA or foreign authorities may require additional data or reject applications. - **Capital and dilution risk** [high] — The company has no product revenue and must fund R&D through external capital. - **Intellectual property and licensing dependence** [high] — Loss of licensed rights or disputes could impair development and commercialization. - Clinical trials may fail, delay, or produce inconclusive results - Regulatory approval is uncertain and can be slow or unpredictable - No approved products means no commercial revenue today - Dependence on licensed IP and collaboration agreements creates counterparty risk - Future commercialization may require manufacturing and reimbursement execution ## Accounting As a clinical-stage biotech, Neumora’s financial statements are driven by R&D expense, acquired in-process R&D, and contingent consideration tied to development milestones. Investors should watch fair value estimates for acquisition-related obligations, lease accounting for office space, and any impairment or remeasurement issues tied to intangible assets and collaboration arrangements. - **Acquired in-process R&D and asset acquisitions** — Can materially affect operating results and balance sheet carrying values - **Contingent consideration and milestone obligations** — Can create volatility in liabilities and earnings - **Lease accounting** — Impacts balance sheet and operating expense presentation - Acquired IPR&D and asset acquisitions can create large upfront expense - Contingent milestone payments may be remeasured and affect earnings - Lease accounting affects operating liabilities and expense timing - No product revenue yet, so future revenue recognition will be event-driven - Clinical-stage estimates are sensitive to trial and approval assumptions --- *Last updated: 2026-04-29T04:41:14.524375+00:00*